WallStSmart
EXOZ

eXoZymes, Inc.

NASDAQ: EXOZ · HEALTHCARE · BIOTECHNOLOGY

$9.88
-1.76% today

Updated 2026-06-02

Market cap
$79.19M
P/E ratio
P/S ratio
EPS (TTM)
$-1.15
Dividend yield
52W range
$7 – $18
Volume
0.0M

eXoZymes, Inc. (EXOZ) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20212022202320242025
Revenue$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$59405.00$147751.00$267382.00
Gross profit$-59405.00$-147751.00$-267382.00
Gross margin
R&D$454454.00$348084.00$527480.00$1.87M$3.71M
SG&A$838391.00$984583.00$1.34M$4.06M$5.91M
Operating income$-1.29M$-1.33M$-1.80M$-5.93M$-9.72M
Operating margin
EBITDA$-1.15M$-1.18M$-1.60M$-5.59M$-9.43M
EBITDA margin
EBIT$-1.21M$-1.33M$-1.80M$-5.86M$-9.72M
Interest expense
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%
Net income$-1.21M$-1.40M$-2.04M$-5.86M$-9.16M
Net income growth (YoY)-15.5%-46.0%-187.5%-56.3%
Profit margin

Frequently asked questions

What is eXoZymes, Inc.'s revenue?

eXoZymes, Inc.'s trailing twelve-month revenue is $-700.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How much free cash flow does EXOZ generate?

EXOZ produced $-6.67M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is EXOZ's balance sheet healthy?

EXOZ holds $3.04M in cash and equivalents against — in long-term debt, on $3.40M of shareholder equity. That debt is best read against the cash flow the business throws off each year.